The trading price of Boston Scientific Corporation (NYSE:BSX) closed lower on Friday, October 08, closing at $43.16, -1.05% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $43.10 and $44.02. The company’s P/E ratio in the trailing 12-month period was 117.28, while its 5Y monthly beta was 0.88. In examining the 52-week price action we see that the stock hit a 52-week high of $46.28 and a 52-week low of $32.99. Over the past month, the stock has lost -4.95% in value.
Boston Scientific Corporation, whose market valuation is $62.11 billion at the time of this writing, is expected to release its quarterly earnings report Oct 27, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0.4 per share this quarter, however they have predicted annual earnings per share of $1.61 for 2021 and $1.87 for 2022. It means analysts are expecting annual earnings per share growth of 67.70% this year and 16.10% next year.
Analysts have forecast the company to bring in revenue of $2.97 billion for the current quarter, with the likely lows of $2.73 billion and highs of $3.04 billion. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $12 billion. The company’s revenue is forecast to grow by 21.10% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Boston Scientific Corporation 1 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BSX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BSX a recommendation rating is 30. Out of them, 5 rate it a Hold, while 22 recommend Buy, whereas 3 assign an Overweight rating. 0 analyst(s) have tagged Boston Scientific Corporation (BSX) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 5.51, which symbolizes a positive outlook. A quick review shows that BSX’s price is currently -1.84% off the SMA20 and -2.84% off the SMA50. The RSI metric on the 14-day chart is currently showing 44.22, and weekly volatility stands at 2.63%. When measured over the past 30 days, the indicator reaches 2.18%. Boston Scientific Corporation (NYSE:BSX)’s beta value is currently sitting at 0.86, while the Average True Range indicator is currently displaying 0.97. With analysts defining $45.00-$57.00 as the low and high price targets, we arrive at a consensus price target of $51.62 for the trailing 12-month period. The current price is about -4.26% off the estimated low and -32.07% off the forecast high, based on this estimate. Investors will be thrilled if BSX’s share price rises to $52.00, which is the median consensus price. At that level, BSX’s share price would be -20.48% below current price.
To see how Boston Scientific Corporation stock has been performing in comparison to its peers in the industry, here are the numbers: BSX stock’s performance was -1.05% in the latest trading, and 6.59% in the past year, while Abbott Laboratories (ABT) has traded 0.41% on the day and positioned 9.07% higher than it was a year ago. Another comparable company Medtronic plc (MDT) saw its stock close -1.23% lower in the most recent trading session but was up 16.21% in a year. Furthermore, Stryker Corporation (SYK) showed a decrease of -0.86% on the day while its price kept inclining at 20.35% over the past year. Boston Scientific Corporation has a P/E ratio of 117.28, compared to Abbott Laboratories’s 33.13 and Medtronic plc’s 43.69. Also in last trading session, the S&P 500 Index has plunged -0.19%, while the Dow Jones Industrial also saw a negative session, down -0.03% on the day.
An evaluation of the daily trading volume of Boston Scientific Corporation (NYSE:BSX) indicates that the 3-month average is 6.39 million.
Currently, records show that 1.42 billion of the company’s shares remain outstanding. The insiders hold 0.20% of outstanding shares, whereas institutions hold 93.80%. However, since the stock’s price has seen 20.06% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.